Resultats de la cerca - Simon Hitier
- Mostrar 1 - 6 resultats de 6
-
1
Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme per Axel Heidenreich, Sergio Bracarda, Malcolm D. Mason, Haluk Özen, Lisa Sengeløv, Inge M. van Oort, Christos N. Papandreou, Sophie D. Fosså, Simon Hitier, Miguel Ángel Climent
Publicat 2014Artigo -
2
21st century headache: mapping new territory per Peter J. Goadsby, Michel Lantéri‐Minet, Martin C. Michel, Mário Fernando Prieto Peres, Mamoru Shibata, Andreas Straube, Tissa Wijeratne, Caty Ebel‐Bitoun, Luminita Constantin, Simon Hitier
Publicat 2021Artigo -
3
Safety of Cabazitaxel + Prednisone (Cbz + P) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Previously Treated with Docetaxel (Doc): Cohort Compassi... per Axel Heidenreich, H Scholz, Hasan Özen, Choosak Pripatnanont, Inge M. van Oort, Winald R. Gerritsen, Eleni Efstathiou, José Augusto Rinck, Jeong Hyun Lee, A. Boumessous, Zhen Su, Simon Hitier, Alexandros Ardavanis
Publicat 2014Artigo -
4
Treatment Patterns in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Previously Treated with Docetaxel (Doc)-Based Chemotherapy (Ctx): Proxima per Hideyuki Akaza, Giuseppe Procopio, Choosak Pripatnanont, Gaetano Facchini, S. Fava, Duncan Wheatley, K.C. Leung, Mohammad Butt, A. Silva, Lucía Castillo, George Fountzilas, Simon Hitier, Evelyne Ecstein-Fraïsse, Samira Bensfia, Mustafa Özgüroğlu
Publicat 2014Artigo -
5
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study per Eric Van Cutsem, C. Boni, Josep Tabernero, Bartomeu Massutí, Gary Middleton, Faysal Dane, Peter Reichardt, Francisco Pimentel, Allen Lee Cohn, Philippe Follana, Michael Clemens, Alberto Zaniboni, Vladimir Moiseyenko, Mark Harrison, Donald Richards, Hans Prenen, Simon Pernot, Evelyne Ecstein-Fraïsse, Simon Hitier, P. Rougier
Publicat 2014Artigo -
6
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized tr... per John R. Mackey, Tadeusz Pieńkowski, John Crown, Saeed Sadeghi, Miguel Martín, Arlene Chan, Mansoor N. Saleh, Sandeep Sehdev, Louise Provencher, Semiglazov Vf, Michael F. Press, Guido Sauter, Mary-Ann Lindsay, Vincent Houé, Marc Buyse, Philippe Drevot, Simon Hitier, Samira Bensfia, W. Eiermann
Publicat 2016Artigo
Eines de cerca:
Matèries relacionades
Medicine
Cancer
Chemotherapy
Docetaxel
Internal medicine
Febrile neutropenia
Neutropenia
Oncology
Androgen deprivation therapy
Cabazitaxel
Prostate cancer
Surgery
Adverse effect
Breast cancer
Regimen
Absenteeism
Capecitabine
Chemotherapy regimen
Colorectal cancer
Cyclophosphamide
Doxorubicin
Environmental health
Fluorouracil
Gastroenterology
Headaches
Leukopenia
Metastatic breast cancer
Mitoxantrone
Neurology
Nursing